Snake/Spider: Enhancing Exposure Therapy for Snake and Spider Phobias

Sponsor
University of Texas at Austin (Other)
Overall Status
Completed
CT.gov ID
NCT02160470
Collaborator
National Institute of Mental Health (NIMH) (NIH)
120
1
4
88
1.4

Study Details

Study Description

Brief Summary

This study tests whether exposure therapy for fear of snakes or spiders is enhanced by the addition of a brief fear retrieval trial prior to treatment, and the use of compound extinction during treatment. The goal of the study is to determine whether these behavioral techniques enhance the efficacy of exposure therapy, one of the most empirically supported treatments for anxiety disorders.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Exposure Therapy with Retrieval
  • Behavioral: Exposure Therapy with Compound Extinction
  • Behavioral: Exposure Therapy with Retrieval and Compound Extinction
  • Behavioral: Therapist-guided Exposure Therapy
Phase 1/Phase 2

Detailed Description

This study tests whether exposure therapy for fear of snakes or spiders is enhanced by the addition of a brief fear retrieval trial prior to treatment, and the use of compound extinction during treatment. The goal of the study is to determine whether these behavioral techniques enhance the efficacy of exposure therapy, one of the most empirically supported treatments for anxiety disorders. Individuals between the ages of 18-65 with elevated fear of spiders or fear of snakes are randomly assigned to one of four treatment conditions (1) standard exposure therapy, (2) exposure therapy with fear retrieval augmentation, (3) exposure therapy with compound extinction augmentation, and (4) exposure therapy with fear retrieval and compound extinction augmentations. All participants undergo an online prescreen and a face-to-face screening assessment to determine eligibility and baseline (pre-treatment) symptom severity. Participants additionally complete assessments directly after treatment (post-treatment), and approximately one week after treatment (follow-up). The pre-treatment assessment occurs 1-14 days prior to treatment, the post-treatment assessment occurs during the treatment visit as soon as the treatment procedure is complete, and the follow-up assessment occurs within a window of 6-14 days after the completion of treatment. Participants complete two behavioral approach tests (in the treatment context and in the generalization context) at pre-treatment, post-treatment, and follow-up. Participants complete a battery of self-report questionnaires at pre-treatment and follow-up.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Factorial Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Enhancing Exposure Therapy for Snake and Spider Phobias With Fear Retrieval and Compound Extinction
Actual Study Start Date :
Aug 1, 2012
Actual Primary Completion Date :
Dec 1, 2019
Actual Study Completion Date :
Dec 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Exposure with Retrieval

Exposure Therapy with Retrieval

Behavioral: Exposure Therapy with Retrieval
Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a fear retrieval trial, which is a brief exposure to the feared stimulus (snake or spider). Based on recent basic science research, the fear retrieval trial is expected to enhance the efficacy of exposure therapy.

Experimental: Exposure with Compounding

Exposure Therapy with Compound Extinction

Behavioral: Exposure Therapy with Compound Extinction
Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. As a component of therapy, participants will receive compound extinction, which consists of exposure to two feared stimuli simultaneously (two spiders or two snakes). Based on recent basic science research, compound extinction is expected to enhance the efficacy of exposure therapy.

Experimental: Exposure with Retrieval and Compounding

Exposure Therapy with Retrieval and Compound Extinction

Behavioral: Exposure Therapy with Retrieval and Compound Extinction
Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a brief fear retrieval trial. As a component of therapy, participants will also receive compound extinction.

Active Comparator: Therapist-Guided Exposure Therapy

Therapist-guided Exposure Therapy

Behavioral: Therapist-guided Exposure Therapy
Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes.

Outcome Measures

Primary Outcome Measures

  1. Change in peak subjective fear (0 - 100), behavioral approach (0 - 4), and heart rate reactivity to a live snake/spider not used during treatment (generalization context) from pre-treatment to follow-up [pre-treatment (window of 1-14 days prior to treatment); follow-up (window of 6-14 days after treatment)]

Secondary Outcome Measures

  1. Change in peak subjective fear (0 - 100), behavioral approach (0 - 4), and heart rate reactivity to a live snake/spider not used during treatment (generalization context) from pre-treatment to post-treatment. [pre-treatment (window of 1-14 days prior to treatment); post-treatment (directly after the treatment procedure is completed)]

  2. Change in peak subjective fear (0 - 100), behavioral approach (1 - 8), and heart rate reactivity to a live snake/spider used during treatment (treatment context) from pre-treatment to follow-up [pre-treatment (window of 1-14 days prior to treatment); follow-up (window of 6-14 days after treatment)]

  3. Change in peak subjective fear (0 - 100), behavioral approach (1 - 8), and heart rate reactivity to a live snake/spider used during treatment (treatment context) from pre-treatment to post-treatment [pre-treatment (window of 1-14 days prior to treatment); post-treatment (directly after the treatment procedure is completed)]

  4. Change in Fear of Snakes/Spiders Questionnaire from pre-treatment to follow-up [pre-treatment (window of 1-14 days prior to treatment); follow-up (window of 6-14 days after treatment)]

  5. Change in Snake/Spider Belief Questionnaire from pre-treatment to follow-up [pre-treatment (window of 1-14 days prior to treatment); follow-up (window of 6-14 days after treatment)]

  6. Change in Agoraphobic Cognitions Questionnaire for Snake/Spider Phobia from pre-treatment to follow-up [pre-treatment (window of 1-14 days prior to treatment); follow-up (window of 6-14 days after treatment)]

  7. Change in Self-Efficacy Questionnaire for Spider/Snake Phobia from pre-treatment to follow-up [pre-treatment (window of 1-14 days prior to treatment); follow-up (window of 6-14 days after treatment)]

  8. Change in Armfield and Mattiske Disgust Questionnaire from pre-treatment to follow-up [pre-treatment (window of 1-14 days prior to treatment); follow-up (window of 6-14 days after treatment)]

  9. Change in Lab for the Study of Anxiety Disorders Specific Phobia Diagnostic Questionnaire from pre-treatment to follow-up [pre-treatment (window of 1-14 days prior to treatment); follow-up (window of 6-14 days after treatment)]

    change from pre-treatment in current phobic diagnostic status and in level of phobic-related distress and impairment

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Age 18 to 65.

  2. Speaks English fluently.

  3. A score of 70 or higher on the Fear of Snakes/Spiders Questionnaire.

  4. Demonstrates avoidance during behavioral approach tests (defined as inability to put palm flat on the bottom of a tank containing a snake/spider, and inability to touch a snake/spider with a bare finger).

Exclusion Criteria:
  1. Unstable dose of psychotropic medications during the 4 weeks prior to baseline assessment.

  2. Currently receiving exposure-based treatment for snake/spider phobia.

  3. Currently at risk for suicide.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Texas at Austin Austin Texas United States 78712

Sponsors and Collaborators

  • University of Texas at Austin
  • National Institute of Mental Health (NIMH)

Investigators

  • Principal Investigator: Michael J Telch, PhD, University of Texas at Austin

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Michael J. Telch, Professor, University of Texas at Austin
ClinicalTrials.gov Identifier:
NCT02160470
Other Study ID Numbers:
  • 2011-10-0012
  • 1F31MH100760-01
First Posted:
Jun 10, 2014
Last Update Posted:
Dec 8, 2020
Last Verified:
Dec 1, 2020
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 8, 2020